Big-data-based edge biomarkers: Study on dynamical drug sensitivity and resistance in individuals

Briefings in Bioinformatics

Volumn 17, Issue 4, 2016, Pages 576-592

  Zeng, Tao ^a   Zhang, Wanwei ^a   Yu, Xiangtian ^b   Liu, Xiaoping ^a   Li, Meiyi ^a   Chen, Luonan ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

big data; Dynamical drug sensitivity and resistance; Dynamical network biomarker; Edge biomarker; Module biomarker; Personalized medicine

Indexed keywords

BIOLOGICAL MARKER;

ALGORITHM; DISEASE EXACERBATION; FACTUAL DATABASE; HUMAN;

ALGORITHMS; BIOMARKERS; DATABASES, FACTUAL; DISEASE PROGRESSION; HUMANS;

EID: 84991380548     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbv078     Document Type: Article

References (126)

1. Auffray C, Charron D, Hood L. Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med 2010;2:57.
2. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011;8:184-7.
3. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol 2012;29:613-24.
4. Highnam G, Mittelman D. Personal genomes and precision medicine. Genome Biol 2012;13:324.
5. Jamal-Hanjani M, Hackshaw A, Ngai Y, et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol 2014;12:e1001906.
6. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014;20:682-8.
7. Stover DG, Wagle N. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. Curr Oncol Rep 2015;17:438.
8. Terry SF. Obama's Precision Medicine Initiative. Genet Test Mol Biomarkers 2015;19:113-14.
9. McCarthy M. Obama seeks $213m to fund "precision medicine". BMJ 2015;350:h587.
10. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-5.
11. Obama 2016 budget calls for precision medicine. Nat Biotechnol 2015;33:216.
12. UK catapults precision medicine. Nat Biotechnol 2015;33:119.
13. Kaiser J. National Institutes of Health. A government niche for translational medicine and drug development. Science 2010;330:1462-3.
14. Milne CP, Kaitin KI. Translational medicine: an engine of change for bringing new technology to community health. Sci Transl Med 2009;1:5cm5.
15. Marko NF, Weil RJ. Mathematical modeling of molecular data in translational medicine: theoretical considerations. Sci Transl Med 2010;2:56rv54.
16. Goodsaid FM, Mendrick DL. Translational medicine and the value of biomarker qualification. Sci Transl Med 2010;2:47ps44.
17. Zhang J. Translational medicine in China. Sci China Life Sci 2012;55:834-6.
18. Howells DW, Sena ES, Macleod MR. Bringing rigour to translational medicine. Nat Rev Neurol 2014;10:37-43.
19. Bornstein SR, Licinio J. Improving the efficacy of translational medicine by optimally integrating health care, academia and industry. Nat Med 2011;17:1567-9.
20. Gordon LB, Rothman FG, Lopez-Otin C, et al. Progeria: a paradigm for translational medicine. Cell 2014;156:400-7.
21. Chen L, Liu R, Liu ZP, et al. Detecting early-warning signals for sudden deterioration of complex diseases by dynamical network biomarkers. Sci Rep 2012;2:342.
22. Buxton B, Hayward V, Pearson I, et al. Big data: the next Google. Interview by Duncan Graham-Rowe. Nature 2008;455:8-9.
23. Jiang B, Song K, Ren J, et al. Comparison of metagenomic samples using sequence signatures. BMC Genomics 2012; 13:730.
24. Feng H, Qin Z, Zhang X. Opportunities and methods for studying alternative splicing in cancer with RNA-Seq. Cancer Lett 2013;340:179-91.
25. Engemann K, Enquist BJ, Sandel B, et al. Limited sampling hampers "big data" estimation of species richness in a tropical biodiversity hotspot. Ecol Evol 2015;5:807-20.
26. Altman RB, Ashley EA. Using "big data" to dissect clinical heterogeneity. Circulation 2015;131:232-3.
27. Li Y, Chen L. Big biological data: challenges and opportunities. Genomics Proteomics Bioinformatics 2014;12:187-9.
28. Wang Y, Zhang XS, Chen L. Computational systems biology in the big data era. BMC Syst Biol 2013;7 (Suppl 2):S1.
29. Liu ZP, Zhang W, Horimoto K, et al. Gaussian graphical model for identifying significantly responsive regulatory networks from time course high-throughput data. IET Syst Biol 2013;7:143-52.
30. Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004;5:101-13.
31. Ideker T, Krogan NJ. Differential network biology. Mol Syst Biol 2012;8:565.
32. Zeng T, Sun SY, Wang Y, et al. Network biomarkers reveal dysfunctional gene regulations during disease progression. FEBS J 2013;280:5682-95.
33. Liu R, Wang X, Aihara K, et al. Early diagnosis of complex diseases by molecular biomarkers, network biomarkers, and dynamical network biomarkers. Med Res Rev 2014;34:455-78. doi:10.1002/med.21293.
34. Zeng T, Zhang W, Yu X, et al. Edge biomarkers for classification and prediction of phenotypes. Sci China Life Sci 2014;57:1103-14.
35. Sahni N, Yi S, Zhong Q, et al. Edgotype: a fundamental link between genotype and phenotype. Curr Opin Genet Dev 2013;23:649-57.
36. Zhang W, Zeng T, Chen L. EdgeMarker: identifying differentially correlated molecule pairs as edge-biomarkers. J Theor Biol 2014;362:35-43.
37. Sun SY, Liu ZP, Zeng T, et al. Spatio-temporal analysis of type 2 diabetes mellitus based on differential expression networks. Sci Rep 2013;3:2268.
38. Lai Y, Wu B, Chen L, et al. A statistical method for identifying differential gene-gene co-expression patterns. Bioinformatics 2004;20:3146-55.
39. Chen L. Systems biology with omics data. Methods 2014;67:267-8.
40. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012;148:1293-307.
41. Zeng T, Wang DC, Wang X, et al. Prediction of dynamical drug sensitivity and resistance by module network rewiring-analysis based on transcriptional profiling. Drug Resist Updat 2014;17:64-76.
42. Zhang W, Zeng T, Liu X, et al. Diagnosing phenotypes of single-sample individuals by edge biomarkers. J Mol Cell Biol 2015;7:231-41.
43. Wang W, Baggerly KA, Knudsen S, et al. Independent validation of a model using cell line chemosensitivity to predict response to therapy. J Natl Cancer Inst 2013;105:1284-91.
44. Reinhold WC, Varma S, Rajapakse VN, et al. Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer. Hum Genet 2015;134:3-11.
45. Kim HS, Minna JD, White MA. GWAS meets TCGA to illuminatemechanisms of cancer predisposition. Cell 2013;152:387-9.
46. Cline MS, Craft B, Swatloski T, et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep 2013;3:2652.
47. Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res 2013;41:D991-5.
48. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: archive for functional genomics data sets-10 years on. Nucleic Acids Res 2011;39:D1005-10.
49. McWilliam H, Li W, Uludag M, et al. Analysis Tool Web Services from the EMBL-EBI. Nucleic Acids Res 2013;41:W597-600.
50. Goujon M, McWilliam H, Li W, et al. A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res 2010;38:W695-9.
51. Sneddon TP, Zhe XS, Edmunds SC, et al. GigaDB: promoting data dissemination and reproducibility. Database (Oxford) 2014;2014:bau018.
52. Sneddon TP, Li P, Edmunds SC. GigaDB: announcing the GigaScience database. Gigascience 2012;1:11.
53. Gerstein M. Genomics: ENCODE leads the way on big data. Nature 2012;489:208.
54. Liu C, Su J, Yang F, et al. Compound signature detection on LINCS L1000 big data. Mol Biosyst 2015;11:714-22.
55. Duan Q, Flynn C, Niepel M, et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res 2014;42:W449-60.
56. Kanehisa M, Goto S, Sato Y, et al. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012;40:D109-14.
57. Ogata H, Goto S, Sato K, et al. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 1999;27:29-34.
58. Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011;39:D561-8.
59. Blake JA, Dolan M, Drabkin H, et al. Gene Ontology annotations and resources. Nucleic Acids Res 2013;41:D530-5.
60. Kellis M, Califano A, Bar-Joseph Z. Preface: RECOMB Conference on Systems Biology, Regulatory Genomics, and DREAM Challenges 2010 special issue. J Comput Biol 2011;18:131.
61. Altman RB. Predicting cancer drug response: advancing the DREAM. Cancer Discov 2015;5:237-8.
62. Feng T, Zhu X. Genome-wide searching of rare genetic variants in WTCCC data. Hum Genet 2010;128:269-80.
63. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
64. Smoot ME, Ono K, Ruscheinski J, et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011;27:431-2.
65. Lopes CT, Franz M, Kazi F, et al. Cytoscape Web: an interactive web-based network browser. Bioinformatics 2010;26:2347-8.
66. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
67. Kramer A, Green J, Pollard J, Jr, et al. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 2014;30:523-30.
68. Abecasis GR, Altshuler D, Auton A, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-73.
69. Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1, 092 human genomes. Nature 2012;491:56-65.
70. The 100, 000 Genomes Project. http://www.genomicseng land.co.uk/the-100000-genomes-project/
71. 100K Wellness Project. http://research.systemsbiology.net/100k/
72. Hood L, Lovejoy JC, Price ND. Integrating big data and actionable health coaching to optimize wellness. BMC Med 2015;13:4.
73. Zeng T, Zhang CC, Zhang W, et al. Deciphering early development of complex diseases by progressive module network. Methods 2014;67:334-43.
74. Liu ZP, Wu H, Zhu J, et al. Systematic identification of transcriptional and post-transcriptional regulations in human respiratory epithelial cells during influenza A virus infection. BMC Bioinformatics 2014;15:336.
75. Bar-Joseph Z, Gitter A, Simon I. Studying and modelling dynamic biological processes using time-series gene expression data. Nat Rev Genet 2012;13:552-64.
76. Wang J, Sun Y, Zheng S, et al. APG: an Active Protein-Gene network model to quantify regulatory signals in complex biological systems. Sci Rep 2013;3:1097.
77. Huang Y, Zaas AK, Rao A, et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLoS Genet 2011;7:e1002234.
78. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
79. Akavia UD, Litvin O, Kim J, et al. An integrated approach to uncover drivers of cancer. Cell 2010;143:1005-17.
80. Chuang HY, Lee E, Liu YT, et al. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007;3:140.
81. Lee E, Chuang HY, Kim JW, et al. Inferring pathway activity toward precise disease classification. PLoS Comput Biol 2008;4:e1000217.
82. Qian L, Zheng H, Zhou H, et al. Classification of time series gene expression in clinical studies via integration of biological network. PLoS One 2013;8:e58383.
83. Li Y, Jin S, Lei L, et al. Deciphering deterioration mechanisms of complex diseases based on the construction of dynamic networks and systems analysis. Sci Rep 2015;5:9283.
84. Zhang S, Liu CC, Li W, et al. Discovery of multi-dimensional modules by integrative analysis of cancer genomic data. Nucleic Acids Res 2012;40:9379-91.
85. De Vlaminck I, Khush KK, Strehl C, et al. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell 2013;155:1178-87.
86. Saeys Y, Inza I, Larranaga P. A review of feature selection techniques in bioinformatics. Bioinformatics 2007; 23:2507-17.
87. Larranaga P, Calvo B, Santana R, et al. Machine learning in bioinformatics. Brief Bioinform 2006;7:86-112.
88. Montero J, Sarosiek KA, DeAngelo JD, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015;160:977-89.
89. Jung Y, Abdel-Fatah TM, Chan SY, et al. SHON is a novel estrogen-regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy. Cancer Res 2013;73:6951-62.
90. Masica DL, Karchin R. Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Cancer Res 2013;73:1699-708.
91. Warsow G, Struckmann S, Kerkhoff C, et al. Differential network analysis applied to preoperative breast cancer chemotherapy response. PLoS One 2013;8:e81784.
92. Zhao J, Zhang XS, Zhang S. Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs. CPT Pharmacometrics Syst Pharmacol 2014;3:e102.
93. Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013;342:967-70.
94. Walsh AJ, Cook RS, Sanders ME, et al. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res 2014;74: 5184-94.
95. Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 2014;15:R47.
96. Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med 2015;21:440-8.
97. Li L, Fridley BL, Kalari K, et al. Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines. BMC Genomics 2014;15:93.
98. Chen CH, Lee CS, Lee MT, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 2014;370:119-28.
99. Cui J, Stahl EA, Saevarsdottir S, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013;9:e1003394.
100. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.
101. Sarashina T, Sakurai T, Watanabe Y, et al. Nucleotide sequence of the hepatitis C virus genome from a patient negative for anti-HCV by the first generation antibody assay. Nucleic Acids Res 1993;21:1037.
102. Lopez-Labrador FX, Ampurdanes S, Gimenez-Barcons M, et al. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon]. Hepatology 1999;29:897-903.
103. Schweitzer CJ, Liang TJ. Impact of host and virus genome variability on HCV replication and response to interferon. Curr Opin Virol 2013;3:501-7.
104. Jornsten R, Wang HY, Welsh WJ, et al. DNA microarray data imputation and significance analysis of differential expression. Bioinformatics 2005;21:4155-61.
105. Rapaport F, Khanin R, Liang Y, et al. Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data. Genome Biol 2013;14:R95.
106. Villoslada P, Baranzini S. Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis. J Neuroimmunol 2012;248:58-65.
107. Baranzini SE, Galwey NW, Wang J, et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet 2009;18:2078-90.
108. Yu X, Li G, Chen L. Prediction and early diagnosis of complex diseases by edge-network. Bioinformatics 2014;30:852-9.
109. Liu R, Yu X, Liu X, et al. Identifying critical transitions of complex diseases based on a single sample. Bioinformatics 2014;30:1579-86.
110. Taylor MW, Tsukahara T, McClintick JN, et al. Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med 2008;6:66.
111. Huang T, Tu K, Shyr Y, et al. The prediction of interferon treatment effects based on time series microarray gene expression profiles. J Transl Med 2008;6:44.
112. Baranzini SE, Mousavi P, Rio J, et al. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol 2005;3:e2.
113. Zeng T, Guo X, Liu J. Negative correlation based gene markers identification in integrative gene expression data. Int J Data Min Bioinform 2014;10:1-17.
114. Lin TH, Kaminski N, Bar-Joseph Z. Alignment and classification of time series gene expression in clinical studies. Bioinformatics 2008;24:i147-55.
115. Vahey MT, Wang Z, Kester KE, et al. Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS, S malaria vaccine. J Infect Dis 2010;201:580-9.
116. Hadley TJ, Peiper SC. From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood 1997;89:3077-91.
117. Maisonneuve C, Bertholet S, Philpott DJ, et al. Unleashing the potential of NOD-and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci USA 2014;111:12294-9.
118. Nardin EH, Oliveira GA, Calvo-Calle JM, et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 2004;72:6519-27.
119. Sallberg M, Hughes J, Jones J, et al. A malaria vaccine candidate based on a hepatitis B virus core platform. Intervirology 2002;45:350-61.
120. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, et al. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005;24:6058-68.
121. Lehrer S. Association between malaria incidence and all cancer mortality in fifty U.S. States and the District of Columbia. Anticancer Res 2010;30:1371-3.
122. Guo Z, Zhang T, Li X, et al. Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics 2005;6:58.
123. Cun Y, Frohlich H. netClass: an R-package for network based, integrative biomarker signature discovery. Bioinformatics 2014;30:1325-6.
124. Winter C, Kristiansen G, Kersting S, et al. Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol 2012;8:e1002511.
125. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013;14:7.
126. Drier Y, Sheffer M, Domany E. Pathway-based personalized analysis of cancer. Proc Natl Acad Sci USA 2013;110:6388-93.